By Matt Grossman

Eli Lilly and Co. and Ypsomed Holding AG will collaborate on an automated insulin delivery system for people with diabetes, the companies said Thursday.

Lilly will be responsible for commercializing the system, which will include an insulin pump that Ypsomed will develop and manufacture.

Ypsomed, based in Switzerland, plans to apply for U.S. Food and Drug Administration clearance for a component of the device in 2022, the companies said. Lilly would have exclusive rights to market the pump in the U.S.

Write to Matt Grossman at matt.grossman@wsj.com

(END) Dow Jones Newswires

11-19-20 0709ET